Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy

Li,Junfeng; Pang,Jinglin; Liu,Yongdong; Zhang,Jing; Zhang,Chuanguang; Shen,Gang; Song,Lili

doi:10.3892/or.2018.6420

Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy

Authors:
- Junfeng Li
- Jinglin Pang
- Yongdong Liu
- Jing Zhang
- Chuanguang Zhang
- Gang Shen
- Lili Song
View Affiliations

Affiliations: Department of Pediatric Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Health Management Center, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Pediatric Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: May 8, 2018 https://doi.org/10.3892/or.2018.6420
Pages: 355-360

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ribonucleotide reductase regulatory subunit M2 (RRM2) is a rate‑limiting enzyme for DNA synthesis and repair. RRM2 has vital roles in controlling the progression of cancer. In the present study, we investigated the RRM2 level in neuroblastoma tissues, analyzed its relationship with clinicopathological characteristics of neuroblastoma patients, and explored the effect of RRM2 on the biological functions of neuroblastoma cells. RRM2 levels in 67 pairs of neuroblastoma and matched adjacent non‑cancerous tissues were detected by qRT‑PCR, and its association with patient clinicopathological features was assessed. Using RRM2 siRNA, the role of RRM2 in cell viability was detected by CCK‑8 assay, and the effects on cell cycle distribution and cell apoptosis were detected by flow cytometry. Hoechst 33342 staining was also performed. For RRM2 protein detection in cells and tissues, western blot analyses were employed. Our results revealed that RRM2 expression was significant higher in neuroblastoma tissues than that noted in adjacent non‑cancerous tissues at both the mRNA and protein levels. The increased RRM2 level was significantly associated with clinical stage. RRM2 levels were suppressed in stage III and IV tumors in the chemotherapy subgroup, compared with levels noted in tumors in the preoperative non‑chemotherapy subgroup. RRM2 siRNA significantly inhibited cell viability in the SH‑5Y5Y cells, induced cell arrest in the G0/G1 phase, and enhanced cell apoptosis. Taken together, overexpression of RRM2 is associated with the genesis and progression of neuroblastoma, and may be a potential chemotherapeutic target.

View Figures

View References

1	Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat Rev Dis Primers. 2:160782016. View Article : Google Scholar : PubMed/NCBI
2	Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG and Weiss WA: The prenatal origins of cancer. Nat Rev Cancer. 14:277–289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Takahashi Y, Sipp D and Enomoto H: Tissue interactions in neural crest cell development and disease. Science. 341:860–863. 2013. View Article : Google Scholar : PubMed/NCBI
4	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
5	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cheung NK and Dyer MA: Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 13:397–411. 2013. View Article : Google Scholar : PubMed/NCBI
7	Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 5:19–33. 2002. View Article : Google Scholar : PubMed/NCBI
8	Lewis CS, Voelkel-Johnson C and Smith CD: Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget. 7:60181–60192. 2016. View Article : Google Scholar : PubMed/NCBI
9	Eriksson S and Martin DW Jr: Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J Biol Chem. 256:9436–9440. 1981.PubMed/NCBI
10	Goan YG, Zhou B, Hu E, Mi S and Yen Y: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
11	Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A and Kasuya K: Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol. 42:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
12	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jung CP, Motwani MV and Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res. 7:2527–2536. 2001.PubMed/NCBI
14	Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res. 385:363–369. 1993.
15	Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang Y, Feng T, Wu J and Liu X: Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-β autocrine loop. Oncotarget. 7:63324–63337. 2016. View Article : Google Scholar : PubMed/NCBI
16	Reece SY and Seyedsayamdost MR: Long-range proton-coupled electron transfer in the Escherichia coli class Ia ribonucleotide reductase. Essays Biochem. 61:281–292. 2017. View Article : Google Scholar : PubMed/NCBI
17	Pai CC and Kearsey SE: A critical balance: dNTPs and the maintenance of genome stability. Genes. 8:pii: E57. 2017. View Article : Google Scholar : PubMed/NCBI
18	Cui JQ, Shi YF, Zhou HJ and Li JQ: The changes of gene expression profiles in hydatidiform mole and choriocarcinoma with hyperplasia of trophoblasts. Int J Gynecol Cancer. 14:984–997. 2004. View Article : Google Scholar : PubMed/NCBI
19	Okamura H, Kamei T, Sakuma N, Hanai N and Ishihara T: Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions. Acta Cytol. 47:209–215. 2003. View Article : Google Scholar : PubMed/NCBI
20	Juhasz A, Vassilakos A, Chew HK, Gandara D and Yen Y: Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 15:1299–1304. 2006.PubMed/NCBI
21	Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T and Fukayama M: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 41:1742–1748. 2010. View Article : Google Scholar : PubMed/NCBI
22	Morikawa T, Maeda D, Kume H, Homma Y and Fukayama M: Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
23	Mannargudi MB and Deb S: Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: Is it a viable cancer therapy? J Cancer Res Clin Oncol. 143:1499–1529. 2017. View Article : Google Scholar : PubMed/NCBI
24	Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW and Whang EE: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery. 136:261–269. 2004. View Article : Google Scholar : PubMed/NCBI
25	Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, et al: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 12:807–817. 2010. View Article : Google Scholar : PubMed/NCBI
26	Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V and Rosell R: Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
27	Moorthy NS, Cerqueira NM, Ramos MJ and Fernandes PA: Development of ribonucleotide reductase inhibitors: A review on structure activity relationships. Mini Rev Med Chem. 13:1862–1872. 2013. View Article : Google Scholar : PubMed/NCBI
28	Cerqueira NM, Pereira S, Fernandes PA and Ramos MJ: Overview of ribonucleotide reductase inhibitors: An appealing target in anti-tumour therapy. Curr Med Chem. 12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
29	Giannattasio M and Branzei D: S-phase checkpoint regulations that preserve replication and chromosome integrity upon dNTP depletion. Cell Mol Life Sci. 74:2361–2380. 2017. View Article : Google Scholar : PubMed/NCBI
30	Dyawanapelly S, Kumar A and Chourasia MK: Lessons learned from gemcitabine: Impact of therapeutic carrier systems and Gemcitabine's drug conjugates on cancer therapy. Crit Rev Ther Drug Carrier Syst. 34:63–96. 2017. View Article : Google Scholar : PubMed/NCBI